AstraZeneca might progressively compensate the U.S. firm for the rights to ivonescimab drug for patients with lung cancer.
As per sources from Bloomberg, Summit has been negotiating with additional significant pharmaceutical firms.
The agreement with AstraZeneca is still under negotiation, but the compensation may involve several billion dollars initially and a number of payments for reaching specific targets, according to some sources.
source: bloomberg.com
